Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
12 Junho 2023 - 9:30AM
Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a
company committed to improving patient outcomes through
diagnostics, radiotherapeutics and artificial intelligence
solutions that enable clinicians to Find, Fight and Follow disease,
announced it will present the following presentations at the
upcoming 2023 Society for Nuclear Medicine and Molecular Imaging
(SNMMI) Annual Meeting, which will be held June 24-27, 2023 in
Chicago, Illinois.
PYLARIFY AI™ (aPROMISE) is the only deep learning enabled
FDA-cleared medical device software to offer standardized PSMA PET
reporting with PYLARIFY AI on PSMA PET/CT images, including those
achieved using PYLARIFY® (piflufolastat F18) PET/CT.1
Standardized PSMA PET reporting provides consistent and precise
disease burden quantification in support of patient management and
tracking over time.2,3,4
“We're thrilled to present compelling data on the real-world
application of AI-enabled PSMA PET imaging at SNMMI,” said Etienne
Montagut, Chief Business Officer, Lantheus. “The presentations by
Dr. Angellica Gordon from UCLA and Dr. Hong Song from Stanford
reflect a significant milestone in our relentless pursuit of
advancing prostate cancer management through cutting-edge
technology and innovation. By harnessing our deep learning
algorithm and extensive datasets, we are committed to sustaining
our efforts to improve guidance for prostate cancer patient
diagnosis and treatment.”
Presentation details are as follows: Date &
Time: Sunday, June 25, 2023, 11:00 am – 12:30 pm
CTSession Title: Physics, Instrumentation &
Data SciencesTitle: Use of aPROMISE as an
artificial intelligence software to automate and standardize
quantitative heterogeneity of PSMA and FDG PET/CT in patients with
mCRPC prior to PSMA radioligand therapy: a proof-of-concept
studyPresenter: Angellica Gordon, MD, PGY-3
Nuclear Medicine Resident, UCLAPoster Number:
P228
Date & Time: Monday, June 26, 2023, 11:15
am – 12:45 pm CTSession Title: Oncology: Clinical
Therapy & Diagnosis (includes Phase 2, Phase 3, post approval
studies)Title: Total and Anatomically
Contextualized Quantitative 18F-DCFPyL PET at biochemical
recurrence predicts subsequent biochemical progression free
survival in prostate cancer patientsPresenter:
Hong Song, MD, Assistant Professor of Radiology (Nuclear Medicine),
StanfordPoster Number: P837
About Lantheus With more than 65 years of
experience in delivering life-changing science, Lantheus is
committed to improving patient outcomes through diagnostics,
radiotherapeutics and artificial intelligence solutions that enable
clinicians to Find, Fight and Follow disease. Lantheus is
headquartered in Massachusetts and has offices in New Jersey,
Canada and Sweden. For more information, visit
www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary
Statements This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, that are subject to risks and
uncertainties and are made pursuant to the safe harbor provisions
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements may be identified by their use of terms
such as “can,” “introduce,” “potential” and other similar terms.
Such forward-looking statements are based upon current plans,
estimates and expectations that are subject to risks and
uncertainties that could cause actual results to materially differ
from those described in the forward-looking statements. The
inclusion of forward-looking statements should not be regarded as a
representation that such plans, estimates and expectations will be
achieved. Readers are cautioned not to place undue reliance on the
forward-looking statements contained herein, which speak only as of
the date hereof. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by law. Risks and uncertainties that could cause our
actual results to materially differ from those described in the
forward-looking statements include (i) our ability to successfully
launch PYLARIFY AI as a commercial product; (ii) the market
receptivity to PYLARIFY AI as a new digital application for
quantitative assessment of PSMA PET/CT images in prostate cancer;
(iii) the intellectual property protection of PYLARIFY AI; (iv)
interruptions or performance problems associated with our digital
application, including a service outage; (v) a network or data
security incident that allows unauthorized access to our network or
data or our customers’ data; and (vi) the risks and uncertainties
discussed in our filings with the Securities and Exchange
Commission (including those described in the Risk Factors section
in our Annual Reports on Form 10-K and our Quarterly Reports on
Form 10-Q).
1https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K2116552https://pubmed.ncbi.nlm.nih.gov/34463809/3https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K220590
4https://jnm.snmjournals.org/content/63/supplement_2/2496
Contacts:Mark KinarneyVice President, Investor
Relations978-671-8842ir@lantheus.com
Melissa DownsSenior Director, Corporate
Communications646-975-2533media@lantheus.com
Lantheus (NASDAQ:LNTH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Lantheus (NASDAQ:LNTH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024